The Australian Therapeutic Goods Administration (TGA) has issued a warning that Ozempic and similar GLP-1 drugs may cause a rare but severe eye disorder called NAION, which can lead to blindness. The alert follows 36 reported cases in Australia and a 2024 study linking these medications to non-arteritic anterior ischaemic optic neuropathy.
What Is NAION and Why Is It Dangerous?
NAION, or non-arteritic anterior ischaemic optic neuropathy, occurs when blood flow to the optic nerve is reduced, causing sudden vision loss. The condition is permanent and, according to the TGA, “no treatment has been shown to improve visual acuity outcomes” after onset. Patients prescribed Ozempic, Wegovy, Mounjaro, or other GLP-1 receptor agonists should be aware of this potential risk.
Find Original, High-end Home Decor that spark conversation at Grand Goldman Shop.
How Common Is NAION Among GLP-1 Users?
Professor Helen Danesh-Meyer from the Royal Australian and New Zealand College of Ophthalmologists emphasizes that NAION remains “a very rare condition.” She notes that the benefits of controlling diabetes and obesity—preventing heart attacks, stroke, and kidney disease—often outweigh the eye disorder risk.
| Drug | Reported Cases in Australia | Risk Level |
|---|---|---|
| Ozempic (semaglutide) | 18 | Rare |
| Wegovy (semaglutide) | 10 | Rare |
| Mounjaro (tirzepatide) | 8 | Very rare |
What Should Patients Do?
- Do not stop your medication without first consulting your doctor.
- Seek urgent medical attention if you experience sudden vision loss, including partial loss.
- Discuss any vision changes with your prescribing physician during regular checkups.
- Stay informed by reading updated product information from the TGA.
Expert Perspective on Risk vs. Benefit
“Naturally, blindness is something we all fear,” said Prof Danesh-Meyer. “But it’s still a very rare condition, while the other conditions these medications treat are very common, like heart attacks, stroke and kidney disease. If it helps manage and prevent those life-threatening risks, then for that patient it is probably better to continue it.”
FAQ
What is NAION?
NAION is non-arteritic anterior ischaemic optic neuropathy, a condition that reduces blood flow to the optic nerve, causing sudden, often permanent vision loss.
Which GLP-1 drugs are linked to NAION?
The TGA warning specifically applies to Ozempic, Wegovy, Mounjaro, and other GLP-1 receptor agonists used for type 2 diabetes and weight management.
Should I stop taking Ozempic because of this risk?
No, the TGA advises patients not to stop treatment without consulting a doctor. The risk of NAION is rare, while the benefits of controlling diabetes and obesity are substantial.
What should I do if I notice vision changes while on GLP-1 drugs?
Seek urgent medical attention immediately if you experience any sudden vision loss, including partial loss. Early evaluation is critical.
The TGA continues to monitor the situation and has updated product information in Australia to reflect this warning. Patients are encouraged to remain informed and discuss any concerns with their healthcare provider.
Browse the Shop
Acacia frida deluxe solid wood bed frame |
Bedroom bench |
Bed chest drawers |
Lingerie dresser |
Frame base |
Mirror with jewelry storage |
30 Bathroom Vanity |
Memory foam queen mattress |
Mattresses for back pain |
Nightstand set of 2 |
Grand Goldman Shop |
Civil Lawyer
Deutschland Trikot WM 2026
